OPA1 and neurodegenerative disease: In addition, downregulated OPA1 has been reported in other neurodegenerative diseases models, such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease (HD), and retinal ischemia–reperfusion-related diseases27–31.